• Home
  • Search Results
  • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

The New England journal of medicine (2015-03-05)
Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, David Porter, Prudence A Francis, Lori J Goldstein, Henry L Gomez, Carlos S Vallejos, Ann H Partridge, Shaker R Dakhil, Agustin A Garcia, Julie Gralow, Janine M Lombard, John F Forbes, Silvana Martino, William E Barlow, Carol J Fabian, Lori Minasian, Frank L Meyskens, Richard D Gelber, Gabriel N Hortobagyi, Kathy S Albain

Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes. We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group). The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range. Rates were compared with the use of conditional logistic regression. Secondary end points included pregnancy outcomes and disease-free and overall survival. At baseline, 218 patients were eligible and could be evaluated. Among 135 with complete primary end-point data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group (odds ratio, 0.30; 95% confidence interval [CI], 0.09 to 0.97; two-sided P=0.04). Owing to missing primary end-point data, sensitivity analyses were performed, and the results were consistent with the main findings. Missing data did not differ according to treatment group or according to the stratification factors of age and planned chemotherapy regimen. Among the 218 patients who could be evaluated, pregnancy occurred in more women in the goserelin group than in the chemotherapy-alone group (21% vs. 11%, P=0.03); women in the goserelin group also had improved disease-free survival (P=0.04) and overall survival (P=0.05). Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility. (Funded by the National Cancer Institute and others; POEMS/S0230 ClinicalTrials.gov number, NCT00068601.).

Product Number
Product Description

Gonadorelin, European Pharmacopoeia (EP) Reference Standard
Goserelin acetate, ≥99% (HPLC), white powder
Goserelin, European Pharmacopoeia (EP) Reference Standard
Goserelin for NMR identification, European Pharmacopoeia (EP) Reference Standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.